Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Piramal Pharma Limited operates as a pharmaceutical company in North America, Europe, Japan, India, and internationally. The company offers a portfolio of pharmaceutical products and services through global development and manufacturing facilities and distribution network. It also operates contract development and manufacturing organization that provides services across the spectrum of the drug life cycle, including discovery, development, and commercial manufacturing of drug substances and products; complex hospital generics business which offers inhalation anesthetics, intrathecal therapy for spasticity management, injectable pain and anesthesia drugs, and other generic and specialty products; and India consumer healthcare business comprising analgesics, skin care, vitamin/mineral supplement, kids' wellness, digestives, women's health, and hygiene and protection. The company was incorporated in 2020 and is based in Mumbai, India.

Revenue projections:

Revenue projections for PPLPHARMA
Revenue projections for PPLPHARMA

PPLPHARMA's revenues are expected to fall below last year's, and this forecast tends to raise concerns among investors. A revenue drop can negatively impact the company's profitability, making investors more cautious about their positions due to the risks of declining financial performance.

Financial Ratios:

currentRatio 1.431000
forwardPE 48.001446
debtToEquity 60.083000
earningsGrowth 0.000000
revenueGrowth -0.088000
grossMargins 0.610460
operatingMargins -0.021600
trailingEps -0.200000
forwardEps 3.154280

PPLPHARMA's current ratio being 1.431 suggests that the company has no issue servicing its short-term debt. Its strong liquidity position, supported by sufficient cash reserves and current assets, ensures that PPLPHARMA can meet its financial obligations with ease.
Piramal Pharma Limited's low growth in earnings and revenue points to a likely reduction in profits. This signals a weakening financial performance, indicating the company might face difficulties in staying profitable.

Price projections:

Price projections for PPLPHARMA
Price projections for PPLPHARMA

Price projections for PPLPHARMA have been steadily revised downward over time, indicating growing concerns about the company's future performance. This downward trend reflects reduced optimism among analysts regarding PPLPHARMA's ability to meet previous expectations.

Recommendation changes over time:

Recommendations trend for PPLPHARMA
Recommendations trend for PPLPHARMA


The recent buy bias from analysts suggests PPLPHARMA is seen as a strong investment, encouraging more investors to consider it. With this favorable sentiment, PPLPHARMA appears to be a reliable option for parking money, offering stability and long-term growth potential in the stock market.